

530,857

10/530857

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau(43) International Publication Date
22 April 2004 (22.04.2004)

PCT

(10) International Publication Number
WO 2004/032923 A1(51) International Patent Classification⁷: **A61K 31/427,**
A61P 35/00Douglas [US/US]; 156 Dean Road, Brookline, MA 02445
(US).(21) International Application Number:
PCT/TB2003/004480(74) Agents: **DOHMANN, George, R.** et al.; Novartis, Corporate Intellectual Property, One Health Plaza Bldg. 430/2, East Hanover, NJ 07936-1080 (US).

(22) International Filing Date: 10 October 2003 (10.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/417,916 11 October 2002 (11.10.2002) US(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.(71) Applicant (*for all designated States except US*): **DANA-FARBER CANCER INSTITUTE INC** [US/US]; 44 Binney Street, Boston; MA 02115 (US).(84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).


(72) Inventors; and

Published:

(75) Inventors/Applicants (*for US only*): **LIN, Boris** [US/US]; 1032 North New Jersey Street, Indianapolis, IN 46202 (US). **ANDERSON, Kenneth, C.** [US/US]; 264 Weston Road, Wellesley, MA 02482 (US). **GRIFFIN, James,**

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **EPOTHILONE DERIVATIVES FOR THE TREATMENT OF MULTIPLE MYELOMA**

(I)

(57) Abstract: The present invention relates to a method of treating a warm-blooded animal, especially a human, having myeloma, especially myeloma which is resistant to conventional cytotoxic chemotherapy, comprising administering to said animal a therapeutically effective amount of an epothilone, especially an epothilone of formula (I), to a combination comprising an epothilone, for simultaneous, separate or sequential use; and to a pharmaceutical composition and a commercial package comprising said combination.

WO 2004/032923 A1